Recent advances in the treatment of colon cancer

Histology and Histopathology

Volumn 21, Issue 7-9, 2006, Pages 867-872

  Xu, R ^a,b   Zhou, B ^b   Fung, P C W ^c   Li, X ^a,b  

^a HUAQIAO UNIVERSITY   (China)

^b Gene Therapy Laboratory   (Greece)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiogenesis; Apoptosis; Chemotherapy; Colon cancer; Immunotherapy

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CETUXIMAB; DOXORUBICIN; EDRECOLOMAB; ENDOSTATIN; FAS LIGAND; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ONCOVAX; OXALIPLATIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASOHIBIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CELL BASED GENE THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; DISEASE FREE SURVIVAL; GENE THERAPY; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COLON TUMOR; GENETICS; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; ONCOLOGY;

COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; MEDICAL ONCOLOGY;

EID: 33746158876     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Brooks P., Clark R. and Cheresh D. (1994). Requirement of vascular intergrin αvβ3 for angiogenesis. Science 264, 569-571.
2. Campos F., Logullo Waitzberg A., Kiss D., Waitzberg D., Habr-Gama A. and Gama-Rodrigues J. (2005). Diet and colorectal cancer: current evidence for etiology and prevention. Nutr. Hosp. 20, 18-25.
3. Chu X., Chen L., Zang J., Wang J., Zhang Q. and Geng H. (2005) Effect of bone marrow-derived monocytes transfected with RNA of mouse colon carcinoma on specific antitumor immunity. World J. Gastroenterol. 11, 760-763.
4. Cook T., Wang Z., Alber S., Liu K., Watkins S., Vodovotz Y., Billiar T. and Blumberg D. (2004). Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res. 64, 8015-80212.
5. Dachs G., Tupper J. and Tozer G. (2005) From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 16, 349-359.
6. DeVita V., Hellman S. and Rosenberg S.(2001). Cancer Principles & Practice of Oncology. 6th edn.
7. Dkhissi F., Lu H., Soria C., Opolon P., Griscelli F., Liu H., Khattar P., Mishal Z., Perricaudet M. and Li H. (2003). Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum. Gene Ther. 14, 997-1008.
8. Eberhart C., Coffey R., Radhika A., Giardiello F., Ferrenbach S. and DuBois R. (1994). Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188.
9. Fearon E. and Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
10. Friedlander M., Theesfeld C., Sugita M., Fruttiger M., Thomas M., Chang S. and Cheresh D. (1996). Involvement of integrins αVβ3 and αVβ5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA 93, 9764-9769.
11. Gianani R., Jarboe E., Orlicky D., Frost M., Bobak J., Lehner R. and Shroyer K. (2001). Expression of survivin in normal, hyperplastic and neoplastic colonic mucosa Hum. Pathol. 32, 119-125
12. Gonciarz M., Pierzchalski P., Lorens K., Pawlik W. and Petelenz M. (2004). Genetic aspects of colorectal carcinogenesis. Wiad Lek.57, 74-79.
13. Grossman D., Kim P.J., Blanc-Brude O.P., Brash D.E., Tognin S., Marchisio P.C. and Altieri D.C. (2001). Transgenic expression of surviving in keratocytes couteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108, 991-999.
14. Guanti G. and Bukvic N. (2000). Hereditary colorectal cancer syndromes. Acta Chir. lugosl. 47, 23-25.
15. Guba M., Seeliger H., Kleespies A., Jauch K. and Bruns C. (2004). Vascular endothelial growth factor in colorectal cancer. Int. J. Colorectal Dis. 19, 510-517
16. Hague A., Hicks D., Hasan F., Smartt H., Cohen G., Paraskeva C. and MacFarlane M. (2005). Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br. J. Cancer 92, 736-742
17. Holliger P., Manzke O., Span M., Hawkins R., Fleischmann B., Qinghua L., Wolf J., Diehl V., Cochet O., Winter G. and Bohlen H. (1999). Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 × anti-CEA bispecific diabodies and B7 × anti-CEA bispecific fusion proteins. Cancer Res. 59, 2909-2916
18. Jain R. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
19. Kawakami M., Furuhata T., Kimura Y., Yamaguchi K., Hata F., Sasaki K. and Hirata K. (2003). Quantification of vascular endothelial growth factor-C and its receptor- 3 messenger RNA with realtime quantitative polymerase chain reaction as a predictor of lymph node metastasis in human colorectal cancer. Surgery 133, 300-308.
20. Kawasaki H., Toyoda M., Shinohara H., Okuda J., Watanabe I., Yamamoto T., Tanaka K., Tenjo T. and Tanigawa N. (2001). Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91, 2026-2032
21. Li H., Lindenmeyer F., Grenet C., Opolon P., Menashi S., Soria C., Yeh P., Perricaudet M. and Lu H. (2001). AdTIMP-2 Inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum. Gene Ther. 12, 515-526.
22. Li M., Wu X. and Xu X. (2001). Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin. Cancer Res. 7, 1010-1016.
23. Lipinski K., Djeha A., Ismail T., Mountain A., Young L. and Wrighton C. (2001). High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol. Ther. 4, 365-371.
24. Longley D. and Johnston P. (2005). Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292.
25. Mack M., Riethmuller G. and Kufer P. (1995). A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 92, 7021-7025
26. Magrini R., Bhonde M., Hanski M., Notter M., Scherubl H., Boland C., Zeitz M. and Hanski C. (2002). Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer 101, 23-31.
27. Mohr A., Henderson G., Dudus L., Herr I., Kuerschner T., Debatin K., Weiher H., Fisher K. and Zwacka R. (2004). AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther. 11, 534-543.
28. Narayan S. and Roy D. (2003). Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol. Cancer 2, 41-55.
29. Okaji Y., Tsuno N., Kitayama J., Saito S., Takahashi T., Kawai K., Yazawa K., Asakage M., Hori N., Watanabe T., Shibata Y., Takahashi K. and Nagawa H. (2004). Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 95, 85-90.
30. Oosterhoff D., Overmeer R., de Graaf M., van der Meulen I., Giaccone G., van Beusechem V., Haisma H., Pinedo H. and Gerritsen W. (2005). Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. Br. J. Cancer 14, 92, 882-887.
31. O'Reilly M., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. Flynn E., Birkhead J., Olsen B. and Folkman J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
32. Parkin D. (2001). Global cancer statistics in the year 2000. Lancet Oncol. 2, 533-543.
33. Parmiani G., Rodolfo M. and Melani C. (2000). Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. Hum. Gene Ther. 11, 1269-1275.
34. Penuelas S., Noe V. and Ciudad C. (2005). Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J. 272, 696-710.
35. Reinmuth N., Liu W., Ahmad S., Fan F., Stoeltzing O., Parikh A., Bucana C., Gallick G., Nickols M., Westlin W. and Ellis L. (2003). Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 63, 2079-2087.
36. Riethmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Funke I., Pichlmaier H., Hirche H., Buggisch P., Witte J. and Pichlmayr R. (1998). Monoclonal antibody therapy for resected Dukes' C colorectal cancer: 7-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16, 1788-1794.
37. Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G., Ghigo D. and Bosia A. (2005). Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 65, 516-525.
38. Saha A., Chatterjee S., Foon K., Primus F., Sreedharan S., Mohanty K. and Bhattacharya-Chatterjee M. (2004). Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res. 64, 4995-5003.
39. Sarela A., Scott N., Ramsdale J., Markham A. and Guillou P. (2001). Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann. Surg. Oncol. 8, 305-310.
40. Schwartzberg L. (2001). Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Oncol. Hematol., 40, 17-/24.
41. Shi J., Zheng D., Man K, Fan S. and Xu RA (2003). TRAIL: a potential agent for cancer therapy. Curr. Mol. Med. 3, 727-736.
42. Shi J., Zheng D., Liu Y, Sham MH, Tam P., Frazaneh F. and Xu RA (2005). Over-expression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 65, 1687-1692.
43. Shimizu K., Watanabe K., Yamashita H., Abe M., Yoshimatsu H., Ohta H., Sonoda H. and Sato Y. (2005). Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem. Biophys. Res. Commun., 327, 700-706
44. Sova P., Ren X., Ni S., Bernt K., Mi J., Kiviat N. and Lieber A. (2004). A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 9, 496-509.
45. Steinbach G., Lynch P., Phillips R., Wallace M., Hawk E., Gordon G., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L. and Levin B. (2000). The effect of celecoxib in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.
46. Teng M., Kershaw M., Moeller M., Smyth M. and Darcy P. (2004). Inmunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther. 15, 699-708
47. Tu S., Cui J., Liston P., Huajiang X., Xu R., Lin M., Zhu Y., Zou B., Ng S., Jiang S., Xia H., Wong W., Chan A., Yuen M., Lam S., Kung H. and Wong B. (2005). Gene therapy for colon cancer by adeno-associated viral Vector-mediated transfer of survivin Cys84Ala mutant. Gastroentology 128, 361-375.
48. Uesato M., Gunji Y., Tomonaga T., Miyazaki S., Shiratori T., Matsubara H., Kouzu T., Shimada H., Nomura F. and Ochiai T. (2004). Synergistic antitumor effect of antiangiogenic factor genes on colon 26 produced by low-voltage electroporation. Cancer Gene Ther. 11, 625-632.
49. Uyl-de Groot C., Vermorken J., Hanna M., Verboom P., Groot M., Bonsel G., Meijer C. and Pinedo H. (2005). Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23, 2379-2387.
50. Watanabe K., Hasegawa Y., Yamashita H., Shimizu K., Ding Y., Abe M., Ohta H., Imagawa K., Hojo K., Maki H., Sonoda H. and Sato Y. (2004). Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest. 114, 898-907.
51. Williams C., Watson A., Sheng H., Helou R., Shao J. and DuBois R. (2000). Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60, 6045-6051.
52. Wils J., O'Dwyer P. and Labianca R. (2001). Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann. Oncol. 12, 13-22.
53. Xu R.A., Sun X., Tse L.Y., Li H., Chan P.C., Xu S., Xiao W., Kung H.F., Krissansen G.W. and Fan S.T. (2003) Long-term expression of angiostatin and suppression of liver metastatic cancer. Hepatology 37, 1451-1461
54. Zhang G., Wang Y., Zhang M., Wang Q., Luo Y., Wang D. and Han C. (2002). Inhibition of growth and metastases of human colon cancer xenograft in nude mice by angiogenesis inhibitor endostatin A.i Zheng 21, 50-53.
55. Zhu H., Guo W., Zhang L., Davis J., Teraishi F., Wu S., Cao X., Daniel J., Smythe W. and Fang B. (2005). Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol. Cancer Ther. 4, 451-456.